"WOO" Windows of Opportunity

[humblehawk]

AEMD @ .35; Heavy ACCUMULATION of issue:

http://stockcharts.com/h-sc/ui?s=AEMD&p=D&yr=0&mn=6&dy=0&id=p07099926804

*Big blocks, some in excess of avg volume, were bought.

Looking to add onto position if it comes in.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Share Statistics
Average Volume (3 month)3: 387,486
Average Volume (10 day)3: 317,456
Shares Outstanding5: 58.52M
Float: 41.52M
% Held by Insiders1: 17.59%
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _


**AEMD's Hemopurifier platform technology, is designed to reduce the presence of infectious viruses from human blood.

**Hemopurifier is a candidate therapeutic device to assist in the treatment of a range of viral pathogens. Viral treatment targets include bio terror agents, pandemic threats, human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS) and hepatitis-C virus (HCV).


* combines the scientific methods of hemodialysis and affinity chromatography as a means to augment the natural immune response of clearing infectious viruses from the blood before the occurrence of cell and organ infection. The Hemopurifier targets to inhibit disease progression of hepatitis-c virus and human immunodeficiency virus, as well as bioterror and pandemic threats.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Aethlon Medical advances therapeutic device for biological warfare pathogens:
http://www.bioprepwatch.com/news/211625-aethlon-medical-advances-therapeutic-device-for-biological-warfare-pathogens

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

CATALYSTS COMING:

More than 65 Hemopurifier treatments have been conducted representing approximately 260 hours of treatment time in multi-stite studies. Research studies have shown that the Hemopurifier is effective in capturing a broad spectrum of viruses considered untreatable with drug therapy, including several diseases considered high risk for bioterror and pandemic threats.

"Based on the clinical data reported, Aethlon has made development of the Hemopurifier for the treatment of chronic hepatitis C its core program," Webber said. "During the final months of the year, the bulk of visible progress took place in improving manufacturing processes in ways necessary for broad commercialization."

____________________________________________________

SHAREHOLDER UPDATE:

http://www.prnewswire.com/news-releases/aethlon-medical-releases-shareholder-update-80891437.html

Key Points:

1. Initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at the Boston University School of Medicine and the Sports Legacy Institute (SLI)

2. Established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of Aethlon Medical to leverage the discovery that our Hemopurifier® captures exosomes known to suppress the immune system in cancer patients.

3. Completed and reported on the "first-in-man" study of a medical device to treat the Human Immunodeficiency Virus (HIV), which demonstrated a 92% reduction of viral load and improved immune function resulting from short-term intermittent application of our Hemopurifier® in the absence of any antiviral drug therapy.

4. Entered into an agreement that extends studies of our Hemopurifier® with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) under a cooperative research and development agreement.

5. Documented our Hemopurifier® effectively captures the current pandemic strain of the H1N1 Swine Flu Virus. During invitro studies, the Hemopurifier® removed 68% of H1N1 virus from blood plasma in 30 minutes, 80% of the virus in two hours, and a 96% reduction of H1N1 was observed at six hours. The studies were performed by third party researchers approved by the United States Department of Health and Human Services (HHS) to house and conduct research with pandemic strains of H1N1 virus.

6. Reported compelling human clinical outcomes against Hepatitis-C virus (HCV) infection; then disclosed a data supported strategy to improve HCV cure rates; and subsequently discovered a clinical validation by Asahi Kasei Kuraray Medical (Asahi) that confirms moderate levels of viral filtration at the outset of standard of care (SOC) therapy can dramatically impact HCV cure rates.

7. Initiated a relationship with Kentucky Bioprocessing LLC (KBP) to establish the processes necessary to support large-scale production of the active affinity agents we immobilize inside our Hemopurifier®. Such affinity agents allow our Hemopurifier® to selectively capture viruses and immunosuppressive proteins from blood and other fluids. The KBP relationship represents an important step towards establishing the long-term commercial feasibility of our Hemopurifier® in the marketplace.

8. Executed a non-exclusive agreement with NextPharma Technologies (Click Here for Website) to establish manufacturing of our Hemopurifier® under good manufacturing practice (GMP) requirements set forth in quality system (QS) regulations for medical device commercialization.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Why could a buyout be in place?

In the HCV treatment world, considerable value is placed upon promising drug candidates. At present, there are a reported 65 drug candidates competing to become a component of standard of care (SOC) drug therapy. Yet, we are uniquely positioned to enhance the benefit of SOC therapy even if the drug combination underlying SOC becomes redefined. Thus, we have an enduring market opportunity that positions us to be an ally with drug developers, not a competitor. The most advanced HCV drug candidate is Telaprevir, which represents a significant value component of the $7+ Billion market valuation enjoyed by Vertex Pharmaceuticals (VRTX). Among the deep pipeline of HCV drug candidates, I am not aware that any has proven to reduce viral load in an HIV-infected individual. Nor am I aware that any candidate has established broad-spectrum activity against bioterror and pandemic threats. Certainly, none of these candidates represent a platform technology that can be leveraged to participate in the cancer marketplace.

*David Webber, RedChip Research Analyst, reported:
"We continue to rate Aethlon Medical a Speculative Buy with a 12-month price target of $1.00 per share. According to management, talks continue with potential partners. As it is not clear when to expect the next substantial increment of clinical data, we consider news of a partnership, should that occur, the potential event with the best chance of moving the stock towards our price target during 2010."
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _